Genmab A/S (GNMSF) to Release Quarterly Earnings on Thursday

Genmab A/S (OTCMKTS:GNMSF) is projected to post its results after the market closes on Thursday, August 6th. Analysts expect the company to post earnings of $3.53 per share and revenue of $1.1110 billion for the quarter.

Genmab A/S Trading Down 2.5%

GNMSF opened at $282.00 on Tuesday. Genmab A/S has a 52 week low of $216.31 and a 52 week high of $352.00. The company has a quick ratio of 2.17, a current ratio of 2.18 and a debt-to-equity ratio of 0.87. The business has a fifty day simple moving average of $266.16 and a 200-day simple moving average of $280.30. The firm has a market cap of $17.36 billion, a P/E ratio of 21.27 and a beta of 0.77.

About Genmab A/S

Genmab A/S is a biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer and other serious diseases. The company’s core expertise lies in its proprietary antibody platforms, including DuoBody®, HexaBody® and HexElect®, which enable the design and engineering of novel bispecific and enhanced-effector antibodies. Genmab’s science-driven approach integrates advanced protein engineering with insights into tumor biology to generate candidates that can engage the immune system, disrupt disease pathways and offer potential safety and efficacy advantages over conventional therapies.

Founded in 1999 and headquartered in Copenhagen, Denmark, Genmab has grown into a global organization with research and development facilities in Utrecht, the Netherlands, and commercial and clinical support offices in the United States.